Kymera Therapeutics Inc (KYMR)
31.14
-0.32
(-1.02%)
USD |
NASDAQ |
Jun 25, 16:00
31.14
0.00 (0.00%)
After-Hours: 20:00
Kymera Therapeutics Shareholders Equity (Quarterly): 711.20M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 711.20M |
| December 31, 2023 | 394.97M |
| September 30, 2023 | 395.54M |
| June 30, 2023 | 435.43M |
| March 31, 2023 | 462.00M |
| December 31, 2022 | 490.15M |
| September 30, 2022 | 512.88M |
| June 30, 2022 | 397.95M |
| March 31, 2022 | 428.72M |
| Date | Value |
|---|---|
| December 31, 2021 | 459.64M |
| September 30, 2021 | 483.14M |
| June 30, 2021 | 258.10M |
| March 31, 2021 | 275.25M |
| December 31, 2020 | 283.89M |
| September 30, 2020 | 294.68M |
| June 30, 2020 | 104.04M |
| December 31, 2019 | -74.41M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-74.41M
Minimum
Dec 2019
711.20M
Maximum
Mar 2024
371.36M
Average
397.95M
Median
Jun 2022
Shareholders Equity (Quarterly) Benchmarks
| SELLAS Life Sciences Group Inc | 9.684M |
| Iovance Biotherapeutics Inc | 680.02M |
| Immunic Inc | 83.58M |
| Protagonist Therapeutics Inc | 560.44M |
| Ovid Therapeutics Inc | 78.28M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 868.25M |
| Total Liabilities (Quarterly) | 157.05M |
| Current Ratio | 9.571 |